NCT00025506 · OUTCOME
Frequency and Severity of Adverse Effects as Assessed by Common Toxicity Criteria (CTC) v2.0
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus · Source last updated 2019-07-24
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Each cycle during treatment and 30 days after the last treatment (average 4 months)
Analysis population: Eligible and evaluable patients
Groups in this outcome
Grade 0
Number of patients who did not experience the adverse event.
Grade 1
Number of patients who experienced a Grade 1 adverse event (Common Toxicity Criteria version 2)
Grade 2
Number of patients who experienced a Grade 2 adverse event (Common Toxicity Criteria version 2)
Grade 3
Number of patients who experienced a Grade 3 adverse event (Common Toxicity Criteria version 2)
Grade 4
Number of patients who experienced a Grade 4 adverse event (Common Toxicity Criteria version 2)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 0 | 45 |
|---|
| Grade 1 | 45 |
|---|
| Grade 2 | 45 |
|---|
| Grade 3 | 45 |
|---|
| Grade 4 | 45 |
|---|
Reported measurements
Nausea
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 31 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Vomiting
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 36 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Constipation
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 27 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Anorexia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 42 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Fatigue
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 22 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 15 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Neutropenia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 41 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Thrombocytopenia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 44 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Anemia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 22 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Cardiovascular
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 31 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
Neuropathy (sensory)
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 27 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Other neurologic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 31 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Dermatologic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 39 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Metabolic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 40 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Pain
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 0 | 38 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 1 | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 0
- title
- Nausea
- categories
- measurements
- group Id
- OG000
- value
- 36
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 0
- title
- Vomiting
- categories
- measurements
- group Id
- OG000
- value
- 27
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 0
- title
- Constipation
- categories
- measurements
- group Id
- OG000
- value
- 42
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- title
- Anorexia
- categories
- measurements
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 5
- group Id
- OG002
- value
- 15
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 0
- title
- Fatigue
- categories
- measurements
- group Id
- OG000
- value
- 41
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- title
- Neutropenia
- categories
- measurements
- group Id
- OG000
- value
- 44
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- title
- Thrombocytopenia
- categories
- measurements
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 1
- title
- Anemia
- categories
- measurements
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 2
- title
- Cardiovascular
- categories
- measurements
- group Id
- OG000
- value
- 27
- group Id
- OG001
- value
- 12
- group Id
- OG002
- value
- 5
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 0
- title
- Neuropathy (sensory)
- categories
- measurements
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 6
- group Id
- OG004
- value
- 0
- title
- Other neurologic
- categories
- measurements
- group Id
- OG000
- value
- 39
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- title
- Dermatologic
- denoms
- counts
- group Id
- OG000
- value
- 45
- group Id
- OG001
- value
- 45
- group Id
- OG002
- value
- 45
- group Id
- OG003
- value
- 45
- group Id
- OG004
- value
- 45
- units
- Participants
- groups
- description
- Number of patients who did not experience the adverse event.
- id
- OG000
- title
- Grade 0
- description
- Number of patients who experienced a Grade 1 adverse event (Common Toxicity Criteria version 2)
- id
- OG001
- title
- Grade 1
- description
- Number of patients who experienced a Grade 2 adverse event (Common Toxicity Criteria version 2)
- id
- OG002
- title
- Grade 2
- description
- Number of patients who experienced a Grade 3 adverse event (Common Toxicity Criteria version 2)
- id
- OG003
- title
- Grade 3
- description
- Number of patients who experienced a Grade 4 adverse event (Common Toxicity Criteria version 2)
- id
- OG004
- title
- Grade 4
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Eligible and evaluable patients
- reporting Status
- POSTED
- time Frame
- Each cycle during treatment and 30 days after the last treatment (average 4 months)
- title
- Frequency and Severity of Adverse Effects as Assessed by Common Toxicity Criteria (CTC) v2.0
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle